Manuscripts
Showing 1587 manuscripts.
ART-free HIV-1 remission in children with in-utero HIV-1
after very early ART (IMPAACT P1115): a multicentre,
open-label, phase 1/2 proof-of-concept study
Citation
Deborah Persaud, Anne Coletti, Bryan S. Nelson, Jennifer Jao, Edmund Capparelli, Diane Costello, Camlin Tierney, Adeodata R. Kekitiinwa, Teacler Nematadzira, Boniface N. Njau, John Moye, Patrick Jean-Philippe, Violet Korutaro, Annet Nalugo, Tapiwa Mbengeranwa, Tinashe Chidemo, Blandina T. Mmbaga, Philoteus A. Sakasaka, Mark Cotton, Cheryl Jennings, Carly Hoffmann, Laura Hovind, Scott Watson, Yvonne Bryson, Ellen G. Chadwick, IMPAACT P1115 Study Team. ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study. New England Journal of Medicine. 2025.Year
2025
Journal
New England Journal of Medicine
Study
P1115
Pharmacokinetics and Safety of Clofazimine in WomenWith Rifampicin-resistant Tuberculosis DuringPregnancy and the Postpartum Period: Results FromIMPAACT P1026s
Citation
Jennifer A. Hughes, Flynn McMorrow, Kristina M. Brooks, Mauricio Pinilla, Lee Fairlie, James S. Ngocho, Alice Stek, Brookie M. Best, Mark Mirochnick, Lubbe Wiesner, Kathleen George, Kevin Knowles, Renee Browning, Tara DeYampert, Anneke C. Hesseling, Eric Decloedt, David E. Shapiro, Ahizechukwu C. Eke, IMPAACT P1026s Protocol Team. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. Journal of Infectious Diseases. 2025. 233: 16-26. PMID: 41165222Year
2025
Journal
Journal of Infectious Diseases
Study
P1026S
Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED
Citation
Tk Nguyen, Jung-Woo Chae, Lauren Ziemba, Anne Coletti, Kevin Knowles, Benjamin Johnston, Patrick Jean-Philippe, Tsungai Mhembere, Tariro Chawana, Deo Wabwire, Violet Korutaro, Sikhulile Moyo, Patricia Mandima, Siphokazi Sibisi, Avy Violari, Sherika Hanley, Blandina Mmbaga, Gaerolwe Masheto, Ponego Ponatshego, Gerhard Theron, Shilpa N Naik, Roger Shapiro, Shahin Lockman, Lameck Chinula, Jeremiah D. Momper, IMPAACT 2010/VESTED Protocol Team. Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED. Journal of Acquired Immune Deficiency Syndromes. 2025. Online ahead of printPMID: 41195894Year
2025
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
IMPAACT 2010
Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices during Pregnancy and Postpartum
Citation
Yifan Yu, Kristina M. Brooks, Gustavo F. Doncel, Brookie M. Best, Mark A. Marzinke, Mark Mirochnick, Peter Anderson, Landon Myer, Connie Celum, Renee Heffron, Jenell Coleman, Dvora Joseph Davey, Craig W. Hendrix, Jeremiah D. Momper, Robert Bies, Rachel K. Scott. Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices during Pregnancy and Postpartum. Clinical Pharmacokinetics. 2025. 65: 133-148. PMID: 41222898Year
2025
Journal
Clinical Pharmacokinetics
Study
P1026S, IMPAACT 2026
Are Family Factors Differentially Associated with Externalizing Symptoms Among Youth with Perinatally Acquired HIV?
Citation
Deborah A G Drabick, Rafaella J Jakubovic, Abbey L Friedman, Valerie S Everett, George O Emory, Marianela Rosales Gerpe, Katherine M Deloreto, Aidan P Campagnolio, Mary Katherine Galante, Sharon Nachman, Kenneth D Gadow. Are Family Factors Differentially Associated with Externalizing Symptoms Among Youth with Perinatally Acquired HIV?. Child Psychiatry & Human Development. 2025. 56: 1559-1572. PMID: 38261149Year
2025
Journal
Child Psychiatry & Human Development
Study
P1055
Postpartum maternal monitoring for renal safety related to tenofovir exposure during breastfeeding in the PROMISE 1077BF randomized trial
Citation
Kristin Baltrusaitis, Camlin Tierney, Mary Glenn Fowler, Maxensia Owor, Teacler G. Nematadzira, Lynette Nyakudya, Haseena Cassim, Jeanne de Jager, Kathleen George, Barbara Heckman, Kevin Knowles, Renee Browning, George K. Siberry, Taha E. Taha, Lynda Stranix-Chibanda, PROMISE P1084s Study Team. Postpartum maternal monitoring for renal safety related to tenofovir exposure during breastfeeding in the PROMISE 1077BF randomized trial. Journal of AIDS. 2025. PMID: 41474755Year
2025
Journal
Journal of AIDS
Study
P1084s
Use of a Medication Management Algorithm in Depressed Youth Living with HIV: Secondary analysis of a multi-site randomized controlled trial
Citation
Graham J. Emslie, Beth D. Kennard, Kristin Baltrusaitis, Sophia M. Jones, Jessica M. Jones, Jaime Deville, Kathy Pitts, David E. Shapiro, Allison Eliscu, Larry K. Brown. Use of a Medication Management Algorithm in Depressed Youth Living with HIV: Secondary analysis of a multi-site randomized controlled trial. Journal of Child and Adolescent Psychopharmacology. 2025. PMID: 41182169Year
2025
Journal
Journal of Child and Adolescent Psychopharmacology
Study
IMPAACT 2002
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
Citation
Mark F Cotton, Patrick Jean-Philippe, Anne Coletti, Ellen G Chadwick, Jennifer Jao, Stephen A Spector, Mark Mirochnick, Edmund V Capparelli, Diane Costello, Joseph Szewczyk, Nicol Nicodimus, Lynda Stranix-Chibanda, Adeodata R Kekitiinwa, Violet Korutaro, Deborah Persaud, Christina Reding, Yvonne Bryson, Mary N Carrington, Bryan S Nelson, Sai Majji, Camlin Tierney, Dwight E Yin. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024. 23: 2352-3018. PMID: 38061376Year
2024
Journal
Lancet HIV
Study
P1115
Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum
Citation
Risa M. Hoffman, Sean Brummel, Lauren Ziemba, Lameck Chinula, Jeffrey S A Stringer, Frances Nakayiwa, Avy Violari, Lee Fairlie, Victoria Ndyanabangi, Teacler G. Nematadzira, Sherika Hanley, Esau João, Linda Aurpibul, Mario Dias Correa Junior, Oranich Navanukroh, Neetal Nevrekar, Gerhard Theron, Cristina Barroso Hofer, Rebecca Zash, Roger Shapiro, Nahida Chakhtoura, Ben Johnston, Chelsea Krotje, Katie McCarthy, Patrick Jean-Philippe, Paul Sax, Judith S. Currier, Shahin Lockman, VESTED Study Team. Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum. Clinical Infectious Diseases. 2024. 78: 1617-1628. PMID: 38180851Year
2024
Journal
Clinical Infectious Diseases
Study
IMPAACT 2010
Bridging Dolutegravir Clinical Viral Response Across Doses and Formulations Using Model-Based Exposure-Response Analysis in Pediatrics
Citation
Hardik Chandasana, Rajendra Singh, Annie Buchanan, Cynthia Brothers, Andy Wiznia, Mattie Bartlett, Stephanie Popson, Ellen Townley, Rohan Hazra, Kathy George, Cindy Vavro, Theodore Ruel, Edward Acosta, IMPAACT P1093 Team. Bridging Dolutegravir Clinical Viral Response Across Doses and Formulations Using Model-Based Exposure-Response Analysis in Pediatrics. Journal of Acquired Immune Deficiency Syndromes. 2024. 8: F11-F18. PMID: 38768443Year
2024
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1093